NCT01913028View on ClinicalTrials.gov

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Healthy
Interventions
DRUG

MEDI9929

1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo

DRUG

Placebo

1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo

Trial Locations (2)

810-0064

Kyushu Clinical Pharmacology Research Clinic, Medical Co. LTA, Fukuoka

Unknown

Research Site, Fukuoka

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

MedImmune LLC
All Listed Sponsors
collaborator

MedImmune LLC

INDUSTRY

lead

AstraZeneca

INDUSTRY